Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants.
Passage of human immunodeficiency virus type-1 (HIV-1) in T-lymphocyte cell lines in the presence of increasing concentrations of the hydroxylethylamino sulfonamide inhibitor VX-478 or VB-11328 results in sequential accumulation of mutations in HIV-1 protease. We have characterized recombinant HIV-1 proteases that contain these mutations either individually (L10F, M46I, I47V, I50V) or in combination (the double mutant L10F/I50V and the triple mutant M46I/I47V/I50V). The catalytic properties and affinities for sulfonamide inhibitors and other classes of inhibitors were determined. For the I50V mutant, the efficiency (kcat/Km) of processing peptides designed to mimic cleavage junctions in the HIV-1 gag-pol polypeptide was decreased up to 25-fold. The triple mutant had a 2-fold higher processing efficiency than the I50V single mutant for peptide substrates with Phe/Pro and Tyr/Pro cleavage sites, suggesting that the M46I and I47V mutations are compensatory. The effects of mutation on processing efficiency were used in conjunction with the inhibition constant (Ki) to evaluate the advantage of the mutation for viral replication in the presence of drug. These analyses support the virological observation that the addition of M46I and I47V mutations on the I50V mutant background enables increased survival of the HIV-1 virus as it replicates in the presence of VX-478. Crystal structures and molecular models of the active site of the HIV-1 protease mutants suggest that changes in the active site can selectively affect the binding energy of inhibitors with little corresponding change in substrate binding.
Pazhanisamy
S
S
Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139, USA.
Stuver
C M
CM
Cullinan
A B
AB
Margolin
N
N
Rao
B G
BG
Livingston
D J
DJ
D000595:Amino Acid Sequence; D001665:Binding Sites; D002219:Carbamates; D005663:Furans; D014644:Genetic Variation; D016333:HIV Protease / Q000187:drug effects / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000494:pharmacology; D015497:HIV-1 / Q000201:enzymology* / Q000235:genetics*; D006868:Hydrolysis; D019469:Indinavir; D007546:Isoquinolines / Q000494:pharmacology; D007700:Kinetics; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009154:Mutation; D009842:Oligopeptides / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D019258:Saquinavir; D012641:Selection, Genetic; D013379:Substrate Specificity; D013449:Sulfonamides / Q000494:pharmacology
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D009842:Oligopeptides; D011725:Pyridines; D011804:Quinolines; D013449:Sulfonamides; C095108:amprenavir; D019469:Indinavir; D016333:HIV Protease; D019258:Saquinavir